AngioDynamics, Inc. (NASDAQ: ANGO) Q4 2025 Earnings | 07/15/2025

About this video

AngioDynamics, Inc. (NASDAQ: ANGO) reported its Q4 2025 results on July 15, 2025, delivering a strong finish to the fiscal year marked by double-digit revenue growth and improved profitability. Pro forma net sales for the quarter reached $80.2 million, an increase of 12.7% year-over-year, led by a 22% surge in Med Tech revenue to $35.8 million. The Med Device segment also contributed, posting $44.4 million in sales, up 6.2% from the prior year. Gross margin for Q4 was 52.7%, impacted by $1.6 million in tariff-related costs, with the Med Tech division’s gross margin at 59.0%. Despite these headwinds, AngioDynamics generated $16.2 million of free cash flow, achieved positive adjusted EBITDA of $3.4 million, and ended the quarter with a cash position of $55.9 million. The company reported a GAAP loss per share of $(0.15) and a pro forma adjusted loss per share of $(0.03), narrowing losses compared to Q4 2024. The company’s continued pivot toward higher-margin Med Tech platforms enabled its third consecutive quarter of Med Tech growth above 20%, driven by expanded adoption of the Auryon platform (sales up 19.7% to $15.6 million) and clinical momentum in NanoKnife, supported by new CPT reimbursement codes for both prostate and pancreatic procedures. U.S. net sales totaled $67.5 million, with international growth accelerating 22.8% to $12.7 million. Management underscored further strategic execution, including a successful revolving credit facility for greater capital flexibility and robust new business wins in key product lines. AngioDynamics highlighted expanded market opportunity—now addressing over $10 billion globally—and pointed to clinical progress and new product launches positioning the firm as a high-growth MedTech player. Looking ahead, guidance for fiscal 2026 projects net sales of $305–$310 million, with Med Tech growth of 12–15% and gross margins between 53.5% and 55.5%. Management targets positive free cash flow for the full year despite ongoing tariff risks and expects pro forma adjusted EBITDA of $3.0–$8.0 million, continuing the company’s turnaround. Outlook: Fiscal 2026 net sales guidance: $305–$310 million Med Tech revenue growth targeted at 12–15% Gross margin expected at 53.5–55.5% Pro forma adjusted EBITDA: $3–8 million Focus on expanding higher-margin MedTech platforms, clinical adoption, and international growth Sustained free cash flow and capital flexibility About Inside Ticker: For more expert analysis and real-time updates on AngioDynamics, Inc. (NASDAQ: ANGO) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #AngioDynamics #ANGO #Q42025 #Earnings #MedTech #Auryon #NanoKnife #FinancialResults #RevenueGrowth #EBITDA #GrossMargin #Tariffs #StockMarket #Investing #InsideTicker #ClinicalInnovation #Healthcare #FreeCashFlow #BusinessUpdate #Guidance #ShareholderReturns #MedicalDevices #USMarket #InternationalGrowth #PlatformExpansion #Q4Results #MarketUpdate